When a wellness product promises to "boost immunity," "support joint health," or "reduce the risk of disease," two U.S. federal agencies may be watching — and they divide the work differently than most consumers expect. The Food and Drug Administration (FDA) primarily governs claims on product labeling, while the Federal Trade Commission (FTC) polices the truthfulness of claims in advertising across every channel. The same sentence can clear the label review and still fail as an ad, because each agency applies a different legal framework to the same product. Exponent, a consulting firm that evaluates consumer health claims, identifies this as the defining structural feature of the landscape: the two agencies' authorities overlap on health product marketing, but neither is interchangeable with the other.

Understanding that split — along with the "competent and reliable scientific evidence" standard that advertising claims must meet — gives readers a workable framework for judging whether a health claim deserves their trust. It also explains a recurring frustration for consumers: why a claim that appears permissible in one context, such as a brand's website, may be problematic in another, such as on the package itself.

Navigating the Regulatory Landscape for Health Claims

The regulatory picture for health and wellness products is complicated by a simple fact: a product's regulatory status can change depending on the claim being made. A wellness device that merely "promotes relaxation" may fall outside device regulation entirely, while a nearly identical product claiming to treat anxiety may be regulated as a medical device. Exponent's analysis of consumer health claims emphasizes this claim-driven shift as a defining feature of the market.

The FDA's Center for Devices and Radiological Health has issued guidance clarifying its compliance policy for low-risk products that promote a healthy lifestyle — so-called general wellness products. Under section 520(o)(1)(B) of the Federal Food, Drug, and Cosmetic (FD&C) Act, software intended "for maintaining or encouraging a healthy lifestyle and is unrelated to the diagnosis, cure, mitigation, prevention, or treatment of a disease or condition" is not a device. FDA's guidance interprets that provision for general wellness products, and the agency notes the guidance does not change or rescind any requirements of the FD&C Act or applicable regulations.

That statutory boundary — wellness on one side, disease on the other — runs through nearly every claim category in this market. It is also narrower than many brands assume: the FDA's device-center guidance does not apply to products such as drugs, biologics, dietary supplements, foods, or cosmetics, which are regulated by other FDA centers. A claim's category and the product class it sits in together determine which rules actually attach.

FDA vs. FTC: Who Regulates What?

The division of labor largely follows the medium. The FDA has primary responsibility for the labeling and branding of foods, drugs, devices, and cosmetics, and it also regulates prescription drug advertising. The FTC, by contrast, oversees advertising truthfulness wherever it appears — press releases, social posts, influencer briefs, and web pages, as industry guidance from 5W Public Relations describes. A brand's promotional website copy is advertising; the words printed on the package and its insert are labeling. The same health statement may therefore be answerable to different regulators depending on where a shopper encounters it.

The two agencies share authority over the marketing of health products, each reviewing the same product from a different angle. Their coordination is outlined in a memorandum of understanding dividing responsibility between them. In practice, the overlap can produce converging enforcement interests: an analysis of general wellness products published in the National Library of Medicine's collection observes that FDA regulatory and enforcement decisions may affect the practices the FTC is charged with regulating, and that the FTC's expertise can be especially relevant where firms "skate the line" with borderline claims.

One structural difference matters for brands: unlike the FDA, the FTC cannot exercise premarket approval over health-related claims. Its leverage comes after publication, through enforcement against claims that are deceptive or unsubstantiated. Practically, this means there is no advertising "sign-off" that clears a claim in advance — a brand carries the substantiation burden from the moment the claim runs, which is why documentation matters.

The Standard: "Competent and Reliable Scientific Evidence"

The FTC's substantiation rule is set out in its Health Products Compliance Guidance. Advertisers must have adequate substantiation — described as robust, reproducible, competent and reliable scientific evidence — before advertising a health-related claim, covering everything the claim conveys expressly or by implication. Two principles anchor the agency's posture: health claims must be truthful and not misleading, with clear and conspicuous disclosure where needed, and the underlying evidence should preferably rest on peer-reviewed guidelines and published methodologies.

How much evidence is enough? As a general matter, the FTC states that substantiation of health-related benefits will need to take the form of randomized, controlled human clinical testing to meet the competent and reliable standard. The agency then evaluates the reliability of that testing against parameters such as sample size, duration, and outcome measures — parameters that vary with the exact nature of the hypothesis being tested and accepted norms in the relevant field. A study that is adequate for one claim may be inadequate for another.

The standard is therefore not a fixed checklist but a proportionality judgment. The more specific and health-consequential the claim, the more rigorous the expected evidence. This proportionality is a general principle derived from the varying standards the two agencies apply; specific requirements are complex and context-dependent, and the guidance leaves room for judgment about what a given claim actually conveys.

Claim Type and Evidence Standard Comparison

The table below maps common claim categories to their primary regulator and the evidence standard a reader should expect behind them. It distinguishes where the claim appears — labeling versus advertising — because that determines which agency's rules govern, and it treats disease language as the highest-scrutiny category.

Health claim categories mapped to primary regulator and expected evidence standard
Claim Type Primary Regulator (Label vs. Ad) Required Evidence Standard
General wellness claims (low-risk devices) — e.g., "enhance learning capacity," "promote relaxation and manage stress." Relate to general well-being, healthy lifestyle, or maintaining a healthy state; do not reference specific diseases. FDA's device center exercises its compliance policy — enforcement discretion — for such labeling on low-risk products; FTC regulates the same claims in advertising. Lower evidence threshold. FDA treats lifestyle software unrelated to disease as outside device regulation; products must not be intended to diagnose, cure, mitigate, treat, or prevent disease.
Wellness claims referencing disease (low-risk devices) — e.g., "may help reduce the risk of" or "may help living well with" a condition. FDA guidance for labeling; FTC for advertising versions. Acceptable only if the relationship is "well understood" and "generally accepted," per the FDA's categorization as described in the wellness-device literature.
Structure/function claims (dietary supplements) — describe a nutrient's or dietary ingredient's role in affecting structure or function in humans, or the documented mechanism by which it maintains structure or function. FDA for labeling; FTC for advertising. Must be truthful and not misleading, with the manufacturer holding substantiation that the claim is truthful. In advertising, FTC standards apply: randomized, controlled human clinical testing is the general expectation for health-related benefits.
Disease treatment or prevention claims — assert a product diagnoses, cures, mitigates, treats, or prevents a specific disease or condition. FDA; such claims often classify the product as a drug or device, triggering more stringent regulation. FTC separately polices these claims in ads. Most demanding. In advertising, claims require the highest level of competent and reliable scientific evidence — with randomized, controlled human clinical testing as the FTC's general benchmark — evaluated against sample size, duration, and outcome measures.

One caution on the final two rows: the underlying guidance does not state that clinical trials are required for every structure/function or disease claim in all contexts. It establishes randomized, controlled human testing as the general form substantiation "will need to take" for health-related benefits, while the FDA's labeling rules for supplements require substantiation that the claim is truthful and not misleading. Requirements are complex and context-dependent.

A Framework for Evaluating Health and Wellness Claims

Putting the pieces together, readers can evaluate any health or wellness claim in four steps:

  1. Locate the claim. Is it on the product label or packaging — FDA's territory — or in an advertisement, website copy, or influencer post, where FTC truthfulness rules govern? The location determines which rulebook applies first.
  2. Classify the claim. Does it reference general well-being and lifestyle (general wellness), the structure or function of the body (structure/function), or a specific disease (treatment or prevention)? The category sets the expected evidence bar, with disease language demanding the most.
  3. Look for the evidence. For advertising claims, the general benchmark is randomized, controlled human clinical testing, judged on sample size, duration, and outcome measures, and preferably grounded in peer-reviewed guidelines and published methodologies. Claims resting only on testimonials, tradition, or single anecdotes should prompt skepticism about whether they meet the standard.
  4. Check for disease language. A product marketed as wellness that slides into disease claims — "reduces the risk of," "helps treat" — may cross into drug or device regulation and demands the strongest substantiation. This is where the line between the FDA's general wellness category and regulated medical products is drawn.

For brands, industry guidance recommends a pre-publication review: substantiate every health, environmental, and performance claim before it runs, check each message against both agencies' rules, and document the review. Because the FTC has no premarket approval process, that documentation becomes the working proof of "adequate substantiation" if the agency ever asks.

Empowering Your Evaluation of Health Claims

When evaluating a health or wellness product claim, first determine whether it appears on the product label, where FDA jurisdiction is primary, or in advertising, where FTC rules control; then assess the claim type — general wellness, structure/function, or disease treatment — to understand the expected level of scientific substantiation. The practical check any reader can apply is the presence of clear, accessible scientific evidence, such as links to studies or citation of reputable scientific consensus, that aligns with the claim type and its regulatory standard. A "promotes relaxation" claim on a low-risk wellness product and a "lowers cholesterol" disease claim in an ad occupy opposite ends of the evidence spectrum; knowing which question to ask of each is the framework in action.

This article covers U.S. federal regulation only — state-level rules and other countries' regimes are beyond its scope — and it addresses health and wellness products generally, including dietary supplements and low-risk devices, without detailing prescription drugs. It is informational and does not constitute legal advice; brands facing enforcement risk or a product launch should confirm their claims with counsel.

Sources